1. Technology & Business Models

2. Intellectual Property

3. Regulatory Concerns

4. Transplantation & Immune Rejection

Reviewing the technology, business models, intellectual property, regulatory concerns, transplantation and immune rejection.

This is the Episode 2 of the Stem Cell Review, aired on October 8st, 2009

1. Different Types of Stem Cells & Future Medical Applications

What are the differences between embryonic, adult and induced pluripotent stem cells? Where do the experts expect the next medical application will be for stem cells? Do stem cells promote regeneration?

2. Stem Cell Interaction and the iPS Cell Revolution

How are cell types interacting? How can induced pluripotent stem (iPS) cells revolutionize drug discovery?

3. The Business & Politics of Stem Cells

Can cell therapies be made into a viable business? How close are we to finding the right business model? Are investors interested in stem cells today? What is the political and ethical landscape like now that the Obama administration has taken over the White House?

This is the Episode 1 of the Stem Cell Review, aired on October 1st, 2009

Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production.

Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, analyst at Rodman & Renshaw. The business model is based on technology licensing, with future ambitions for own product development. Majid and Reni review comparables, Vivalis’ cash position, Euronext vs. NASDAQ listing, and the potential for acquisitions.

This interview was conducted at the NASDAQ Marketsite, on July 17th, 2008, in New York City.

Featuring:

• Dr. Majid Mehtali, CSO of Vivalis Reni Benjamin, Managing Director & Senior Biotechnology Analyst at Rodman & Renshaw
• Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV

DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.